Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine

danegaptidePositive

AI Analysis

Summary

Breye Therapeutics published a paper on its oral danegaptide treatment for non-proliferative diabetic retinopathy (NPDR) in Science Translational Medicine, a prestigious peer-reviewed journal.

Outcome Details

Paper published in Science Translational Medicine

Importance:4/10

Sentiment:

0.40

publicationoral formulationNPDRpeer-reviewedScience Translational Medicine

Related Companies

$SHWZ

Read the original article

Published by GlobeNewswire Clinical Studies on September 23, 2026 6:00 PM

Read Original